EXEL vs. ZBH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXEL and ZBH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EXEL | ZBH |
|---|---|---|
| Company Name | Exelixis, Inc. | Zimmer Biomet Holdings, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 10.36 billion USD | 20.45 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | April 17, 2000 | July 25, 2001 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EXEL and ZBH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXEL | ZBH |
|---|---|---|
| 5-Day Price Return | 2.94% | 4.87% |
| 13-Week Price Return | 4.08% | 5.09% |
| 26-Week Price Return | 14.32% | 0.52% |
| 52-Week Price Return | 42.93% | -3.53% |
| Month-to-Date Return | 6.27% | 12.62% |
| Year-to-Date Return | 15.59% | -2.28% |
| 10-Day Avg. Volume | 3.51M | 2.17M |
| 3-Month Avg. Volume | 3.38M | 2.25M |
| 3-Month Volatility | 62.34% | 27.26% |
| Beta | 0.36 | 0.69 |
Profitability
Return on Equity (TTM)
EXEL
27.74%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, EXEL’s Return on Equity of 27.74% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ZBH
6.62%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
ZBH’s Return on Equity of 6.62% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
EXEL
27.01%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 27.01% places EXEL in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
ZBH
10.51%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
ZBH’s Net Profit Margin of 10.51% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
EXEL
31.38%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 31.38% places EXEL in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
ZBH
16.09%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
ZBH’s Operating Profit Margin of 16.09% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | EXEL | ZBH |
|---|---|---|
| Return on Equity (TTM) | 27.74% | 6.62% |
| Return on Assets (TTM) | 21.09% | 3.74% |
| Net Profit Margin (TTM) | 27.01% | 10.51% |
| Operating Profit Margin (TTM) | 31.38% | 16.09% |
| Gross Profit Margin (TTM) | 96.59% | 71.06% |
Financial Strength
Current Ratio (MRQ)
EXEL
3.51
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
EXEL’s Current Ratio of 3.51 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
ZBH
1.87
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
ZBH’s Current Ratio of 1.87 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EXEL
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
EXEL’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ZBH
0.60
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
ZBH’s Debt-to-Equity Ratio of 0.60 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EXEL
42.74
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
EXEL’s Interest Coverage Ratio of 42.74 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
ZBH
5.76
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
ZBH’s Interest Coverage Ratio of 5.76 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | EXEL | ZBH |
|---|---|---|
| Current Ratio (MRQ) | 3.51 | 1.87 |
| Quick Ratio (MRQ) | 3.22 | 0.80 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.60 |
| Interest Coverage Ratio (TTM) | 42.74 | 5.76 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ZBH
1.02%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
ZBH’s Dividend Yield of 1.02% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ZBH
23.39%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
ZBH’s Dividend Payout Ratio of 23.39% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | EXEL | ZBH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.02% |
| Dividend Payout Ratio (TTM) | 0.00% | 23.39% |
Valuation
Price-to-Earnings Ratio (TTM)
EXEL
17.18
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
EXEL’s P/E Ratio of 17.18 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ZBH
22.82
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
In the lower quartile for the Health Care Equipment & Supplies industry, ZBH’s P/E Ratio of 22.82 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
EXEL
4.64
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
EXEL’s P/S Ratio of 4.64 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ZBH
2.40
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
ZBH’s P/S Ratio of 2.40 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
EXEL
6.19
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
EXEL’s P/B Ratio of 6.19 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
ZBH
1.44
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
ZBH’s P/B Ratio of 1.44 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | EXEL | ZBH |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 17.18 | 22.82 |
| Price-to-Sales Ratio (TTM) | 4.64 | 2.40 |
| Price-to-Book Ratio (MRQ) | 6.19 | 1.44 |
| Price-to-Free Cash Flow Ratio (TTM) | 13.72 | 15.78 |